KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Idexx Laboratories (IDXX) EBT (2016 - 2025)

Historic EBT for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $344.8 million.

  • Idexx Laboratories' EBT rose 1534.31% to $344.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 1651.08%. This contributed to the annual value of $1.1 billion for FY2024, which is 458.5% up from last year.
  • Latest data reveals that Idexx Laboratories reported EBT of $344.8 million as of Q3 2025, which was up 1534.31% from $362.4 million recorded in Q2 2025.
  • Over the past 5 years, Idexx Laboratories' EBT peaked at $362.4 million during Q2 2025, and registered a low of $171.1 million during Q2 2022.
  • Over the past 5 years, Idexx Laboratories' median EBT value was $256.4 million (recorded in 2024), while the average stood at $260.6 million.
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 7553.9% in 2021, then crashed by 3203.74% in 2022.
  • Idexx Laboratories' EBT (Quarter) stood at $191.9 million in 2021, then increased by 11.12% to $213.2 million in 2022, then grew by 12.41% to $239.7 million in 2023, then grew by 6.98% to $256.4 million in 2024, then skyrocketed by 34.47% to $344.8 million in 2025.
  • Its EBT stands at $344.8 million for Q3 2025, versus $362.4 million for Q2 2025 and $310.1 million for Q1 2025.